ANVISA approval for the Spectrila® marketing authorization transfer enables SteinCares to ensure uninterrupted access to essential Acute Lymphoblastic Leukemia (ALL) treatment in Brazil. The milestone strengthens SteinCares’ onco-hematology portfolio and...
San Jose, Costa Rica, January 19th, 2026 — SteinCares announced today that Moody’s Investors Service has assigned the company an AA credit rating with Stable outlook, highlighting its solid financial position, resilient business model, and disciplined operational...
SteinCares strengthens its role as the regional partner for global pharmaceutical companies seeking to bring innovative therapies to Latin American patients. Through this agreement, the company will continue to expand access to innovative, high-quality, and...
This new agreement marks the fourth product in the partnership and introduces a potential cost-effective alternative to one of the world’s top-selling biologics—broadening access to specialty care for patients with chronic inflammatory diseases. The partnership...
This deal strengthens SteinCares’ leadership in the biosimilar segment across Latin America with this treatment for diverse ophthalmological diseases. The partnership will result in significant cost savings for institutions in the region by providing access to a...
